- Theralase (TLT) grants stock options
- It has granted an aggregate of 7,860,000 stock options to directors, officers, employees & advisory board members
- The options granted are exercisable for C$0.25 each and vest over three years, expiring five years from the date of the grant
- The stock option plan was last approved by the shareholders of the company
- Theralase Technologies (TLT) is up 10 per cent, trading at C$0.28 at 1:12 pm EST
Theralase Technologies (TLT) has announced the grant of stock options.
The company uses its light-activated Photo Dynamic Compounds and their associated drug formulations, used to destroy various cancers, bacteria and viruses safely and effectively
It has granted 7,860,000 stock options to directors, officers, employees & advisory board members under the company’s stock option plan.
The options granted are exercisable for C$0.25 each, vest over three years, and expire five years from the grant date.
The company’s shareholders last approved the stock option plan at the Annual General and Special Meeting of Shareholders held on June 28, 2022.
Theralase® is a clinical-stage pharmaceutical company with a primary objective of efficacy and a secondary goal of safety in destroying various cancers, bacteria and viruses.
Theralase Technologies (TLT) is up 10 per cent, trading at C$0.28 at 1:12 pm EST.
